EP1210138A4 - Controlled delivery of bisphosphonates - Google Patents

Controlled delivery of bisphosphonates

Info

Publication number
EP1210138A4
EP1210138A4 EP00928260A EP00928260A EP1210138A4 EP 1210138 A4 EP1210138 A4 EP 1210138A4 EP 00928260 A EP00928260 A EP 00928260A EP 00928260 A EP00928260 A EP 00928260A EP 1210138 A4 EP1210138 A4 EP 1210138A4
Authority
EP
European Patent Office
Prior art keywords
bisphosphonates
controlled delivery
delivery
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00928260A
Other languages
German (de)
French (fr)
Other versions
EP1210138A1 (en
Inventor
Petr Kuzma
Agis Kydonieus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valera Pharmaceuticals Inc
Original Assignee
Valera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valera Pharmaceuticals Inc filed Critical Valera Pharmaceuticals Inc
Publication of EP1210138A1 publication Critical patent/EP1210138A1/en
Publication of EP1210138A4 publication Critical patent/EP1210138A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00928260A 1999-04-22 2000-04-19 Controlled delivery of bisphosphonates Withdrawn EP1210138A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13072899P 1999-04-22 1999-04-22
US130728P 1999-04-22
PCT/US2000/010696 WO2000064516A1 (en) 1999-04-22 2000-04-19 Controlled delivery of bisphosphonates

Publications (2)

Publication Number Publication Date
EP1210138A1 EP1210138A1 (en) 2002-06-05
EP1210138A4 true EP1210138A4 (en) 2003-05-07

Family

ID=22446043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00928260A Withdrawn EP1210138A4 (en) 1999-04-22 2000-04-19 Controlled delivery of bisphosphonates

Country Status (4)

Country Link
EP (1) EP1210138A4 (en)
AU (1) AU4652100A (en)
CA (1) CA2370769A1 (en)
WO (1) WO2000064516A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
FR2803521B1 (en) * 2000-01-12 2002-10-25 Ceva Sante Animale USE OF TILUDRONIC ACID AND ITS DERIVATIVES IN POULTRY FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR PREVENTING AND TREATING OSTEOPOROSIS
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
WO2002062352A2 (en) * 2001-02-07 2002-08-15 Durect Corporation Devices and methods for management of bone density
KR20020080018A (en) * 2001-04-10 2002-10-23 한국화학연구원 A controlled/sustained implant delivery containing bisphosphonate
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
FI20031120A0 (en) * 2003-07-31 2003-07-31 Bci Bioabsorbable Concepts Ltd Multifunctional implant device
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
WO2010111627A1 (en) * 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US8399023B2 (en) 2009-07-31 2013-03-19 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20130064861A1 (en) * 2010-02-17 2013-03-14 Zvi Schwartz Compositions and methods for modifying in vivo calcification of hydrogels
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JO3394B1 (en) * 2014-07-04 2019-10-20 Osteo Pharma B V Compositions and products for use in the treatment of bone fractures and defects
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
WO2019232114A1 (en) * 2018-06-01 2019-12-05 The University Of North Carolina At Chapel Hill Injectable thermoresponsive hydrogels as a combinatory modality for controlled drug delivery, biomaterial implant and 3d printing bioink

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US5338731A (en) * 1989-08-20 1994-08-16 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, processes for preparation and pharmaceutical compositions containing the same
JPH08141067A (en) * 1994-11-16 1996-06-04 Olympus Optical Co Ltd Vital implantation member
US5733564A (en) * 1993-04-14 1998-03-31 Leiras Oy Method of treating endo-osteal materials with a bisphosphonate solution

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014455A1 (en) * 1992-12-23 1994-07-07 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
AU5973496A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
US5338731A (en) * 1989-08-20 1994-08-16 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, processes for preparation and pharmaceutical compositions containing the same
US5733564A (en) * 1993-04-14 1998-03-31 Leiras Oy Method of treating endo-osteal materials with a bisphosphonate solution
JPH08141067A (en) * 1994-11-16 1996-06-04 Olympus Optical Co Ltd Vital implantation member

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199632, Derwent World Patents Index; Class B07, AN 1996-316679, XP002233498 *
DENISSEN H ET AL: "ALVEOLAR BONE RESPONSE TO SUBMERGED BISPHOSPHONATE-COMPLEXED HYDROXYAPATITE IMPLANTS", JOURNAL OF PERIODONTOLOGY, AMERICAN ACADEMY OF PERIODONTOLOGY, CHICAGO, IL, US, vol. 71, no. 2, February 2000 (2000-02-01), pages 279 - 286, XP008010275, ISSN: 0022-3492 *
GOLOMB G ET AL: "CHARACTERIZATION AND ANTICALCIFICATION EFFECTS OF IMPLANTABLE POLYURETHANE MATRICES CONTAINING AMORPHOUS DISPERSION OF BISPHOSPHONIC ACID", CLINICAL MATERIALS, ELSEVIER, GB, vol. 8, no. 1/2, 1991, pages 33 - 42, XP002063577, ISSN: 0267-6605 *
GOLOMB G ET AL: "CONTROLLED RELEASE OF DIPHOSPHONATE TO INHIBIT BIOPROSTHETIC HEART VALVE CALCIFICATION: DOSE-RESPONSE AND MECHANISTIC STUDIES", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 4, no. 3, 1986, pages 181 - 194, XP000653819, ISSN: 0168-3659 *
JOHNSTON T P ET AL: "SITE-SPECIFIC DELIVERY OF ETHANEHYDROXY DIPHOSPHONATE FROM REFILLABLE POLYURETHANE RESERVOIRS TO INHIBIT BIOPROSTHETIC TISSUE CALCIFICATION", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 25, no. 3, 1 June 1993 (1993-06-01), pages 227 - 240, XP000369909, ISSN: 0168-3659 *
PATASHNIK S ET AL: "PREPARATION AND EVALUATION OF CHITOSAN MICROSPHERES CONTAINING BISPHOSPHONATES", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 4, no. 6, 1997, pages 371 - 380, XP000874480, ISSN: 1061-186X *
SABOKBAR A ET AL: "Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 57, no. 10, October 1998 (1998-10-01), pages 614 - 618, XP002953301, ISSN: 0003-4967 *
See also references of WO0064516A1 *
VYAVAHARE N R ET AL: "Synergism of calcium-ethanehydroxybisphosphonate (CaEHBP) and FeCl3: controlled release polymers for preventing calcification of bioprosthetic aortic wall", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 34, no. 2, 1 May 1995 (1995-05-01), pages 97 - 108, XP004037508, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
EP1210138A1 (en) 2002-06-05
CA2370769A1 (en) 2000-11-02
AU4652100A (en) 2000-11-10
WO2000064516A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
EP1210138A4 (en) Controlled delivery of bisphosphonates
IL142807A0 (en) Controlled delivery of active agents
IL137650A0 (en) Drug delivery devices
IL154134A0 (en) Vaginal delivery of bisphosphonates
IL149663A0 (en) Devices for the delivery of drugs having antiprogestinic properties
HK1079718A1 (en) Intracardiac drug delivery
GB0003427D0 (en) Medical nebulizer
GB2335583B (en) Controlling delivery of radiotherapy
GB9900222D0 (en) Therapeutic compounds
GB2352314B (en) Delivery system
GB0011066D0 (en) Delivery system
GB9924158D0 (en) Nebuliser
GB9930160D0 (en) Drug delivery
GB9914960D0 (en) Delivery system
GB9927525D0 (en) Delivery of substances
GB9804768D0 (en) Drug delivery
GB9904304D0 (en) Drug delivery
GB9923578D0 (en) Nebulizers
GB9913060D0 (en) Aromatherapy
GB9923273D0 (en) Medicament delivery system
GB9905134D0 (en) Medicament delivery system
GB9917470D0 (en) Medicament delivery system
GB9903090D0 (en) Therapeutic compounds
GB9907227D0 (en) Therapeutic compounds
GB9914952D0 (en) Therapeutic compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HYDRO MED SCIENCES, INC.,

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/00 B

Ipc: 7A 61L 27/12 B

Ipc: 7A 61K 47/32 B

Ipc: 7A 61K 31/66 A

Ipc: 7A 61L 27/54 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030320

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030526